Here’s a simple rundown of recent news from several pharmaceutical companies. Insmed reported that their new drug, Brinsupri, which treats a chronic lung condition, made nearly $145 million in its first full quarter. This is much more than expected and has analysts excited about its future sales. Johnson & Johnson agreed to offer lower drug prices in exchange for avoiding certain tariffs. They will also build new facilities in the U.S. as part of their commitment to boost manufacturing. Madrigal Pharmaceuticals licensed a drug from Pfizer that they believe could work well with their existing drug, Rezdiffra. This could help reduce liver fat and improve treatment outcomes. Moonlake Immunotherapeutics announced that they might not need another trial to gain approval for their skin disease drug, sonelokimab. This is good news after previous mixed results. Eli Lilly found that combining their obesity drug, Zepbound, with their autoimmune drug, Taltz, helped with weight loss and reduced signs of psoriatic arthritis. Finally, Lexeo Therapeutics and Johnson & Johnson are working on a new way to deliver gene therapies to the heart using a special heart pump technology. This could make the treatments more effective and safer.